The AMLo Board

CHIEF EXECUTIVE OFFICER

Dr Marie Labus

Dr Marie Labus has over 16 years business experience including managing a spin-out company. In that time she has also undertaken leading roles in research strategy development, change management and various business development activities. Marie has significant experience in facilitating, developing and supporting a large and diverse portfolio of enterprise-related activities including protecting intellectual assets, project management, knowledge transfer, consultancy, CPD, patents, licensing, commercial services and Research and Development activities with the aim of commercialisation of research findings for patient benefit.

CHIEF SCIENTIFIC OFFICER

Professor Penny Lovat

Professor Penny Lovat MPhil, PhD is an academic professor at Newcastle University and a founder and director of AMLo Biosciences. With over 25 years of experience of international translational research, Penny’s current AMLo research focusses on the identification and validation of novel biomarkers for cutaneous malignancy and head and neck cancers as well as the development of novel drug targets. Penny has served as a panel member for leading skin research funding bodies including the British Skin Foundation as well as an associate editor for The British Journal of Dermatology and is a recipient of funding from the European Commission, national research councils and the national cancer institute. Attesting to her international recognition Penny has published in excess of 80 peer reviewed articles and has ongoing collaborations in the USA, Europe and commercial sector.

CHIEF MARKETING OFFICER

Jane Meaney

Jane holds a BSc in Biology from the University of York and an MBA from Bradford University. During her 10 years with Shire Pharmaceuticals, from its very early evolution to post-IPO, she launched at least 5 products in UK and Europe. Thereafter experience in 3 start-up biopharma companies provided valuable academic-to-commercialisation experience and involvement in fund-raising, particularly in cancer biomarkers. Jane’s 25+ years of biopharma marketing experience spans many therapy areas with particular expertise in cancers and development of biomarkers supported by digital pathology platforms.

NON-EXECUTIVE DIRECTOR

David Macdonald

David Macdonald has served in CEO and COO roles for over 25 years, most recently as the CEO at First Light Diagnostics, and formerly as a Division President, COO and Vice President at Quest Diagnostics. He has raised over USD $160 million privately in both equity and debt financings and he has led a series of companies through successful exits. He is a result-oriented, decisive leader with biotech industry expertise in a wide variety of medical diagnostic systems, molecular diagnostics, personalized medicine, pharma collaboration, medical devices, research products, and laboratory services. He has an extensive successful track record in M&A integration, fundraising, strategic planning, and business plan execution in complex life science companies, large and small, public, and private.

David has been an invited speaker at a variety of industry events and has served on several industry Advisory Boards and Boards of Directors. He holds a BSBA degree in Management and Finance from Northeastern University in Boston and an MBA from Babson College, Massachusetts, with a focus on Marketing and Entrepreneurship.

INVESTOR REPRESENTATIVE

Dr. Ala Alenazi

Ala is a Principal at Ascension Life Fund and is responsible for sourcing, due diligence and portfolio management. Ala’s investment expertise lies in early-stage techbio in the UK where she has led on several deals and is a board member, delivered university lectures and contributed to UK think tanks and white papers on the subject. Ala is a Molecular Geneticists by background with a PhD from Cambridge University. She also ran the UK and Ireland accelerator arm of Europe’s largest healthcare consortium: EIT Health.

INVESTOR REPRESENTATIVE

Alex Buchan

Alex Buchan PhD is a biologist by background with a PhD in industrial Biotechnology. After a spell in the City he spent 12 years commercialising technologies in fields as diverse as field testing for industrial contaminants, GMOs and bioinformatics. Since 2004 he has worked for Northstar ventures investing in early stage technology companies in the North East of England with a particular focus on life science spin outs from the region’s universities. He currently has an active portfolio of 12 businesses across diagnostics, cell culture, model systems for efficacy & toxicity testing and health informatics.

INVESTOR REPRESENTATIVE

Guy Pengelley

Guy Pengelley represents Future Planet Capital as Portfolio Manager for their BIF Opportunities Fund, a specialist Life Sciences and AgTech venture capital fund investing in UK university spinouts at Series A/B stage. Guy is responsible for sourcing future investment opportunities as well as supporting the fund’s existing portfolio, which includes spinouts from the universities of Oxford, Cambridge, Newcastle, Exeter and Edinburgh. Prior to joining Future Planet Capital, Guy qualified as a Chartered Accountant within Deloitte’s corporate finance division before working at Peel Hunt in their investment banking / M&A team.

INVESTOR REPRESENTATIVE

Dean Slagel

Dean Slagel is Managing Director of Esperante and has 30 years of pharmaceutical industry and life science venture investment experience. Starting his industry career in international marketing management at Tillotts Pharma, he worked for 10 years at Ferring in International Marketing and Business Development management and was Director of Global Business Development prior to his departure to lead Esperante in 2004. Since this time, Esperante has completed 25 investments in therapeutics and diagnostics and has executed 4 successful exits. In addition to AMLo Biosciences, Dean is a Director of Oxford Cancer Biomarkers and a Board Observer at Arquer Diagnostics, Momentum Biosciences and Silenseed.